Metabolic Surgery Cuts Cardiovascular Events for Obesity, Sleep Apnea
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, July 6, 2023 -- Metabolic surgery is associated with a lower risk for major adverse cardiovascular events (MACE) in patients with obstructive sleep apnea (OSA) and obesity, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from June 25 to 29 in Las Vegas.
Ali Aminian, M.D., from the Cleveland Clinic, and colleagues investigated the long-term relationship between metabolic surgery and incident MACE (composite of coronary artery events, cerebrovascular events, heart failure, atrial fibrillation, and mortality) in patients with moderate-to-severe OSA. The analysis included 13,657 adult patients (970 in the metabolic surgery group and 12,687 patients in the nonsurgical control group) with a body mass index of 35 to 70 kg/m² and presence of moderate-to-severe OSA.
The researchers found that the cumulative incidence of MACE at 10 years was 27.3 percent in the metabolic surgery group and 34.1 percent in the nonsurgical group, yielding an adjusted absolute risk difference of 4.2 percent (adjusted hazard ratio, 0.63).
"No other therapy has been shown to reduce the risk of dying or developing heart attack or heart failure in patients with obesity and obstructive sleep apnea," Aminian said in a statement. "Bariatric surgery is a very powerful tool that can help patients with sleep apnea live longer and healthier lives."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD
WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
Statins Reduce CVD Risk in Adults Aged 75 to 85 and 85 Years and Older
TUESDAY, May 28, 2024 -- For patients aged 75 years and older, statin therapy is associated with a risk reduction in cardiovascular diseases (CVDs), according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.